Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|June 2, 2022
Honey bee venom re-challenge during specific immunotherapy: prolonged cardio-pulmonary resuscitation allowed survival in a case of near fatal anaphylaxisSara Micaletto, Kurt Ruetzler, Martin Bruesch, et al.Clinical and Translational Allergy|October 22, 2019
Risk factors for severe systemic sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patientsDanielle Fehr, Sara Micaletto, Thomas Moehr, et al.The Oncologist|September 4, 2020
Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant MelanomaAlexandra Valeska Matter, Sara Micaletto, Ursula Urner-Bloch, et al.ESMO Open|August 20, 2019
How I treat metastatic melanomaReinhard Dummer, Joanna Mangana, Anna Lisa Frauchiger, et al.Clinical Reviews in Allergy & Immunology|July 28, 2017
Urticaria and Angioedema: an Update on Classification and PathogenesisSusanne Radonjic-Hoesli, Kathrin Scherer Hofmeier, Sara Micaletto, et al.Current Oncology Reports|September 26, 2018
The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the GlobeFlorentia Dimitriou, Regina Krattinger, Egle Ramelyte, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 TherapySimone M Goldinger, Pascale Stieger, Barbara Meier, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 26, 2018
Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic MelanomaFlorentia Dimitriou, Alexandra V Matter, Joanna Mangana, et al.ESMO Open|August 11, 2018
Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanomaReinhard Dummer, Olivier Michielin, Mirjam Chantal Nägeli, et al.Oncotarget|December 6, 2019
Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2S310F mutated extramammary Paget's diseaseThierry M Nordmann, Olivia Messerli-Odermatt, Larissa Meier, et al.Pageof 1